

Contents

1	Statistics in Drug Development	1
	By Christy Chuang-Stein and Ralph D'Agostino	
1.1	Introduction	1
1.2	Statistical Support to Non-Clinical Activities	2
1.3	Statistical Support to Clinical Testing	3
1.4	Battling a High Phase III Failure Rate	4
1.5	Do Statisticians Count?	5
1.6	Emerging Opportunities	5
1.7	Summary	6
	References	6
2	Modern Classification Methods for Drug Discovery	7
	By Kjell Johnson and William Rayens	
2.1	Introduction	7
2.2	Motivating Example	9
2.3	Boosting	10
2.4	Model Building	27
2.5	Partial Least Squares for Discrimination	33
2.6	Summary	42
	References	42
3	Model Building Techniques in Drug Discovery	45
	By Kimberly Crimin and Thomas Vidmar	
3.1	Introduction	45
3.2	Example: Solubility Data	46
3.3	Training and Test Set Selection	47
3.4	Variable Selection	51
3.5	Statistical Procedures for Model Building	58
3.6	Determining When a New Observation Is Not in a Training Set	61
3.7	Using SAS Enterprise Miner	63
3.8	Summary	67
	References	67

4	Statistical Considerations in Analytical Method Validation	69
	By Bruno Boulanger, Viswanath Devanaryan, Walthère Dewé, and Wendell Smith	
4.1	Introduction	69
4.2	Validation Criteria	73
4.3	Response Function or Calibration Curve	74
4.4	Linearity	83
4.5	Accuracy and Precision	85
4.6	Decision Rule	88
4.7	Limits of Quantification and Range of the Assay	92
4.8	Limit of Detection	93
4.9	Summary	93
4.10	Terminology	94
	References	94
5	Some Statistical Considerations in Nonclinical Safety Assessment	97
	By Wherly Hoffman, Cindy Lee, Alan Chiang, Kevin Guo, and Daniel Ness	
5.1	Overview of Nonclinical Safety Assessment	97
5.2	Key Statistical Aspects of Toxicology Studies	98
5.3	Randomization in Toxicology Studies	99
5.4	Power Evaluation in a Two-Factor Model for QT Interval	102
5.5	Statistical Analysis of a One-Factor Design with Repeated Measures	106
5.6	Summary	113
	Acknowledgments	115
	References	115
6	Nonparametric Methods in Pharmaceutical Statistics	117
	By Paul Juneau	
6.1	Introduction	117
6.2	Two Independent Samples Setting	118
6.3	The One-Way Layout	129
6.4	Power Determination in a Purely Nonparametric Sense	144
	Acknowledgments	149
	References	149
7	Optimal Design of Experiments in Pharmaceutical Applications	151
	By Valerii Fedorov, Robert Gagnon, Sergei Leonov, and Yuehui Wu	
7.1	Optimal Design Problem	152
7.2	Quantal Dose-Response Models	159
7.3	Nonlinear Regression Models with a Continuous Response	165
7.4	Regression Models with Unknown Parameters in the Variance Function	169
7.5	Models with a Bounded Response (Beta Models)	172
7.6	Models with a Bounded Response (Logit Link)	176
7.7	Bivariate Probit Models for Correlated Binary Responses	181
7.8	Pharmacokinetic Models with Multiple Measurements per Patient	184

7.9	Models with Cost Constraints	190	
7.10	Summary	192	
	References	193	
8	Analysis of Human Pharmacokinetic Data		197
	By Scott Patterson and Brian Smith		
8.1	Introduction	197	
8.2	Bioequivalence Testing	199	
8.3	Assessing Dose Linearity	204	
8.4	Summary	209	
	References	209	
9	Allocation in Randomized Clinical Trials		213
	By Olga Kuznetsova and Anastasia Ivanova		
9.1	Introduction	213	
9.2	Permuted Block Randomization	214	
9.3	Variations of Permuted Block Randomization	217	
9.4	Allocations Balanced on Baseline Covariates	228	
9.5	Summary	233	
	Acknowledgments	233	
	References	233	
10	Sample-Size Analysis for Traditional Hypothesis Testing: Concepts and Issues		237
	By Ralph G. O'Brien and John Castelloe		
10.1	Introduction	238	
10.2	Research Question 1: Does "QCA" Decrease Mortality in Children with Severe Malaria?	240	
10.3	p -Values, α , β and Power	241	
10.4	A Classical Power Analysis	243	
10.5	Beyond α and β : Crucial Type I and Type II Error Rates	249	
10.6	Research Question 1, Continued: Crucial Error Rates for Mortality Analysis	251	
10.7	Research Question 2: Does "QCA" Affect the "Elysemine: Elysemate" Ratios (EER)?	253	
10.8	Crucial Error Rates When the Null Hypothesis Is Likely to Be True	262	
10.9	Table of Crucial Error Rates	263	
10.10	Summary	263	
	Acknowledgments	264	
	References	264	
	Appendix A Guidelines for "Statistical Considerations" Sections	264	
	Appendix B SAS Macro Code to Automate the Programming	265	
11	Design and Analysis of Dose-Ranging Clinical Studies		273
	By Alex Dmitrienko, Kathleen Fritsch, Jason Hsu, and Stephen Ruberg		
11.1	Introduction	273	
11.2	Design Considerations	277	

11.3	Detection of Dose-Response Trends	280	
11.4	Regression Modeling	289	
11.5	Dose-Finding Procedures	294	
11.6	Summary	309	
	References	310	
12	Analysis of Incomplete Data		313
	By Geert Molenberghs, Caroline Beunckens, Herbert Thijs, Ivy Jansen, Geert Verbeke, Michael Kenward, and Kristel Van Steen		
12.1	Introduction	314	
12.2	Case Studies	316	
12.3	Data Setting and Modeling Framework	318	
12.4	Simple Methods and MCAR	319	
12.5	MAR Methods	320	
12.6	Categorical Data	322	
12.7	MNAR Modeling	340	
12.8	Sensitivity Analysis	347	
12.9	Summary	356	
	References	356	
13	Reliability and Validity: Assessing the Psychometric Properties of Rating Scales		361
	By Douglas Faries and Ilker Yalcin		
13.1	Introduction	361	
13.2	Reliability	362	
13.3	Validity and Other Topics	376	
13.4	Summary	382	
	References	383	
14	Decision Analysis in Drug Development		385
	By Carl-Fredrik Burman, Andy Grieve, and Stephen Senn		
14.1	Introduction	385	
14.2	Introductory Example: Stop or Go?	386	
14.3	The Structure of a Decision Analysis	392	
14.4	The Go/No Go Problem Revisited	394	
14.5	Optimal Sample Size	397	
14.6	Sequential Designs in Clinical Trials	406	
14.7	Selection of an Optimal Dose	412	
14.8	Project Prioritization	421	
14.9	Summary	426	
	Acknowledgments	426	
	References	426	
	Index		429